[1]黎 妍 罗伟生.中医药防治肝纤维化的研究进展[J].大众科技,2018,20(09):52-54.
　Research Progress on Prevention and Treatment of Liver Fibrosis with Traditional Chinese Medicine[J].Popular Science & Technology,2018,20(09):52-54.
点击复制

中医药防治肝纤维化的研究进展()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
20
期数:
2018年09
页码:
52-54
栏目:
医药与卫生
出版日期:
2018-09-20

文章信息/Info

Title:
Research Progress on Prevention and Treatment of Liver Fibrosis with Traditional Chinese Medicine
作者:
黎 妍 罗伟生
（广西中医药大学，广西 南宁 530023）
关键词:
中医药; 肝纤维化; 综述
Keywords:
traditional Chinese medicine;  liver fibrosis;  review
文献标志码:
A
摘要:
肝纤维化是由指多种致病因子所致的肝内结缔组织异常增生，导致肝内弥漫性细胞外基质过度沉积的一个病理过程。近年来，中医药学在抗肝纤维化方面积累了丰富的临床经验，在肝纤维化领域取得了较显著的治疗效果，文章对已报道的单味药及中药复方制剂治疗肝纤维化进行综述，并逐一举例说明其治疗效果及作用机制，为今后研发防治肝纤维化的中成药提供新的方向。
Abstract:
Hepatic fibrosis is a pathological process which refers to the abnormal proliferation of connective tissue caused by many pathogenic factors and leads to the excessive deposition of diffuse extracellular matrix in the liver. In recent years, Chinese medicine has accumulated rich clinical experience in anti-hepatic fibrosis, and has achieved remarkable therapeutic effect in the field of liver fibrosis. In this paper, the treatments of liver fibrosis with single Chinese medicine and compound preparation of traditional Chinese medicine are reviewed, and their therapeutic effect and mechanism are illustrated one by one, which provides a new direction for the development of Chinese patent medicine for the prevention and treatment of liver fibrosis in the future.

参考文献/References:

[1] 胡明政,秦春宏.肝纤维化发病机制的研究进展[J].西南军医,2017,19(2):155-157. [2] 国家药典委员会.中华人民共和国药典:一部[S].北京:中国医药科技出版社,2010:263-264. [3] 窦立雯,孙晓倩,李晓宇,等.柴胡水提成分对改良法肝纤维化大鼠的预防作用研究[J].中国药物警戒,2015,12(10): 577-581. [4] Dang SS,Wang BF,Cheng YA,et al.Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats [J].World J Gastroenterol,2007,13(4):557-563. [5] 袁媛,吴芹,石京山,等.丹参及其主要成分保肝作用的研究进展[J].中国中药杂志,2015,40(4):588-593. [6] Wang CY,Ma FL,Liu JT,et al.Protective effect of salvianic acid a on acute liver injury induced by carbon tetrachloride in rats[J].Biol Pharm Bull,2007,30(1):44-47. [7] Qu W,Huang H,Li K,et al.Danshensu-mediated protective effect against hepatic fibrosis induced by carbon tetrachloride in rats [J].Pathologie Biologie,2014,62(6):348- 353. [8] 彭汝琴,王绍展,王媛媛,等.丹参素通过MEK/ERK信号通路抑制肝纤维化[J].中南药学,2017,15(5):580-586. [9] 钟锋,顾健,张亮亮,等.莪术药理作用的现代研究进展[J].中国民族民间医药,2010,19(13):67-68. [10] 臧文华,唐德才,冯海红.莪术不同品种含药血清对人肝癌细胞SMMC7721增殖、凋亡、细胞周期及核质比的影响[J].时珍国医国药,2014,25(8):1797-1799. [11] 王佳丽,王秀,夏泉,等.莪术油中3种倍半萜类化合物对肝癌HepG2细胞增殖抑制作用的研究[J].中成药,2014,36(7): 1535-1539. [12] 张季,宋嬿,王巧晗,等.生、醋莪术对大鼠免疫性肝纤维化及HSC-T6增殖和α-SMA,ProcollagenⅠ表达的影响[J].中国中药杂志,2017,42(13):2538-2545. [13] 王悦,姜雪,丁菲,等.中药苦参药理作用及应用研究进展[J].山东化工,2017,46(15):66-67,69. [14] 钱利强,高泉根,沈根海,等.苦参碱类生物碱及其衍生物抗肝癌作用研究进展[J].实用肿瘤杂志,2015,30(1):97-100. [15] 郑幼兰,彭华毅.氧化苦参碱(苦参素)治疗慢性乙型肝炎、肝纤维化的基础与临床[J].海峡药学,2007,19(1):1-4. [16] 郭守强.苦参碱对肝纤维化大鼠转化生长因子β_1表达的影响[J].西部中医药,2014,27(6):13-15. [17] 郭土深,王辉.苦参素治疗乙肝所致肝纤维化的临床药理研究[J].中国民族民间医药,2016,25(1):114-115. [18] 王强,钟丽华,于雷,等.藏红花对肝纤维化大鼠肝组织TGF-β1表达的影响[J].现代生物医学进展,2012,12(17): 3228-3231. [19] 李伟镇,张旭红,黄清松.红花总黄素对肝纤维化大鼠肝功能和相关血清指标的影响[J].江西中医药,2014,45(10): 46-48. [20] 靳雅玲,罗伟生,欧士钰,等.荔枝核总黄酮对肝纤维化大鼠肝细胞凋亡机制的研究[J].时珍国医国药,2012,23(9): 2197-2199. [21] 喻勤,傅向阳,罗伟生,等.荔枝核总黄酮对大鼠肝纤维化TGF-β/Smad信号通路的影响[J].中国实验方剂学杂志, 2013,19(18):223-227. [22] 赵亮,于苏淮.替比夫定联合复方鳖甲软肝片对慢性乙型病毒性肝炎患者肝功能的影响及对肝纤维化的预防作用[J].临床合理用药杂志,2017,10(34):67-69. [23] 张海涛,张雨晴.复方鳖甲软肝片对乙肝肝纤维化患者疗效及血清TGF-β_1、TNF-α、IL-6水平的影响[J].山东医药,2017,57(34):36-38. [24] 张正行,孙国兴.复方鳖甲软肝片联合丹参注射液治疗慢性乙型肝炎肝纤维化[J].临床医学,2008,28(11):114-115. [25] 姜冬冬,卢秉久.安络化纤丸对小鼠肝纤维化治疗作用的实验研究[J].临床合理用药杂志,2013,6(6):27-29. [26] 王统华,周喜汉,何守搞,等.安络化纤丸辅助治疗对乙型肝炎肝硬化患者血清炎性因子、肝纤维化指标及免疫功能的影响[J].海南医学院学报,2017,23(16):2184-2187.

相似文献/References:

[1]李瑞祥 陈斯宁.中医药对 COPD 大鼠模型作用机理的研究进展[J].大众科技,2014,16(05):95.
[2]廖咸硕.慢性乙型肝炎中医药治疗进展[J].大众科技,2014,16(10):124.
　Progress in the treatment of chronic hepatitis B with traditional Chinese medicine[J].Popular Science & Technology,2014,16(09):124.
[3]李鹏程 韦艾凌 张永琴 唐秋媛.中医药调控肝癌血管生成的研究近况[J].大众科技,2014,16(11):136.
　Research status on traditional Chinese medicine of angiogenesis inhepatocellular carcinoma[J].Popular Science & Technology,2014,16(09):136.
[4]万 媛.中医药协同治疗卒中后抑郁症的研究近况[J].大众科技,2014,16(12):98.
　The recent clinical research of Chinese-western therapy on post-stroke depression[J].Popular Science & Technology,2014,16(09):98.
[5]杨 赟 梁爱武.中医药对慢性阻塞性肺疾病MMP-9、TIMP-1 影响的研究进展[J].大众科技,2015,15(02):78.
　慢性阻塞性肺疾病；基质金属蛋白酶-9；金属蛋白酶组织抑制-1；气道重塑；中医药[J].Popular Science & Technology,2015,15(09):78.
[6]唐梦华,吴玉强.治疗肝纤维化瑶药复方黄根方的研究进展[J].大众科技,2019,21(09):63.
　Research Progress of Cmpound HuangGen of Guangxi Yao Medicine in theTreatment of Hepatic Fibrosis[J].Popular Science & Technology,2019,21(09):63.
[7]张艳娟,吴 光.中医药院校助力精准扶贫工作研究——以广西中医药大学定点扶贫为例[J].大众科技,2019,21(09):129.
　Research on Targeted Poverty Alleviation Work in Colleges and Universities of Traditional Chinese Medicine ——Take Guangxi University of Traditional Chinese Medicine as an Example[J].Popular Science & Technology,2019,21(09):129.
[8]陈曹华　李沛桢　周华亮　马潍珩　刘汝专.中医药治疗腰椎间盘突出症术后残留症状的研究进展[J].大众科技,2022,24(06):112.
　Research Status of Postoperative Residual Symptoms of Lumbar Intervertebral Disc Herniation Treated with Traditional Chinese Medicine[J].Popular Science & Technology,2022,24(09):112.
[9]杨寿松 张龄予 吕 超 刘辉华 陆石俊 覃武海 张荣臻.棒柄花叶清肝胶囊联合替诺福韦治疗慢性乙肝肝纤维化患者的疗效观察[J].大众科技,2022,24(06):124.
　Observation on the Curative Effect of Bangbing Huaye Qinggan Capsule Combined with Tenofovir in the Treatment of Chronic Hepatitis B Patients with Liver Fibrosis[J].Popular Science & Technology,2022,24(09):124.
[10]桂雄斌 伏广虎.中医药治疗变应性鼻炎研究进展[J].大众科技,2018,20(06):61.

备注/Memo

备注/Memo:
【收稿日期】2018-07-06 【基金项目】国家自然科学基金（8166150270）。 【作者简介】黎妍（1994－）女，广西中医药大学住院医师，硕士研究生。
更新日期/Last Update: 2018-10-11